Floatz logo

Ribociclib

Luminal A Breast Carcinoma

Explore 3 assets in Luminal A Breast Carcinoma →
Floatz Rating
B57/100
Confidence
Indicative
v0.2
Sponsor
University Hospital, Akershus
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05163106CT.gov
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Luminal A Breast Carcinoma

AssetSponsorPhaseRating
Ribociclib (this asset)University Hospital, AkershusP2B · 57
GoserelinUniversity Hospital, AkershusP2B
LetrozoleUniversity Hospital, AkershusP2B

Other indications for Ribociclib

IndicationSponsorPhaseRating
Hormone Receptor-Positive Breast Cancer—P4BBB · 73
Breast Cancer—P4BB · 70
Estrogen-Receptor Positive Breast Cancer—P3BB · 69

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Ribociclib in Luminal A Breast Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/ribociclib-luminal-a-breast-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →